|1.||Arjmandi, Bahram H: 3 articles (08/2008 - 02/2005)|
|2.||Lee, Myung G: 2 articles (12/2009 - 10/2006)|
|3.||Chung, Hye J: 2 articles (12/2009 - 10/2006)|
|4.||Khalil, Dania A: 2 articles (08/2008 - 01/2006)|
|5.||Devareddy, Latha: 2 articles (01/2006 - 02/2005)|
|6.||Soung, Do Y: 2 articles (01/2006 - 02/2005)|
|7.||Vieira, Carolina S: 1 article (01/2015)|
|8.||Candido Dos Reis, Francisco José: 1 article (01/2015)|
|9.||Ferriani, Rui A: 1 article (01/2015)|
|10.||Brito, Luiz Gustavo: 1 article (01/2015)|
02/01/2005 - "Different types of ipriflavone (IF) have been reported to be effective when used as a remedy for bone loss due to osteoporosis. "
01/01/1997 - "To confirm the efficacy of ipriflavone on the prevention of vertebral fractures and its effects on bone mineral density in women with postmenopausal established osteoporosis, a large multicentric European study is being conducted. "
01/01/1997 - "Efficacy of ipriflavone in established osteoporosis and long-term safety."
03/01/2007 - "Adding 25 ppm of ipriflavone to the feed appears to be close to an ideal level for clinical treatment of osteoporosis because of improved egg production while maintaining bone mineral content."
06/01/1994 - "[Experimental study on the effect of ipriflavone against osteoporosis in ovariectomized rats]."
01/01/1995 - "Experimental and clinical studies have shown that ipriflavone, a non-hormonal isoflavone derivative, is effective in the prevention and treatment of postmenopausal osteoporosis. "
10/01/1992 - "Experimental and clinical data have shown that ipriflavone is effective in the treatment of established postmenopausal osteoporosis. "
06/01/1998 - "Recently, a large multicentral study, Ipriflavone Multicenter European Fracture Study (IMEFS), was designed in order to investigate the efficacy of ipriflavone on the prevention of vertebral and the effect on BMD in women with postmenopausal osteoporosis."
01/01/1997 - "In order to investigate the efficacy of ipriflavone (i.p.) on the prevention of vertebral fractures and the effect on bone mineral density (BMD) in women with postmenopausal osteoporosis, a large multicentric European study was designed and is presently ongoing. "
03/01/1994 - "Our results support the efficacy of ipriflavone in the treatment of postmenopausal osteoporosis. "
01/01/2014 - "1. Ipriflavone (IP) has been widely studied in humans and is effective for inhibiting osteoclastic bone resorption and enhancing osteoblastic bone formation. "
06/01/1998 - "Ipriflavone has been shown to be effective in reducing bone turnover rate mainly through an inhibition of bone resorption, and has been effect to stimulate of bone formation. "
01/01/1999 - "In vitro studies have shown that ipriflavone affects both bone formation and bone resorption, but the effect in early-stage postmenopausal women with low bone mass and a high turnover of bone metabolism is unknown. "
01/01/1997 - "The aim of this study was to investigate the possible inhibitory effect of ipriflavone on bone resorption in rats. "
09/01/1993 - "To study the effect of ipriflavone on osteoclast-mediated bone resorption and new osteoclast formation, we used an unfractionated bone cell culture system containing mature osteoclasts from femur and tibia of newborn mice. "
08/01/2002 - "Our results show that ipriflavone not only directly inhibits the growth of cancer cells but also reduces osteoclasts to prevent the soft tissue tumor burden and osteolytic bone metastases. "
08/01/2008 - "The findings of this study imply that the combination of genistin and ipriflavone is effective in suppressing mammary methylnitrosurea-induced tumorigenesis and also the lipid environment of the tumor cells that impact tumor growth or proliferation. "
08/01/2002 - "Daily oral administration of ipriflavone at 12 mg/mouse significantly inhibited the development of new osteolytic bone metastases (p < 0.05) and the progression of established osteolytic lesions (p = 0.01), prolonging the life of tumor-bearing mice (p = 0.01 vs. control). "
07/01/2001 - "Ipriflavone efficaciously alleviated the adverse effects of estrogen deficiency such as bone loss and increase in LDL-C level, and the ability of leuprolide therapy to reduce myoma volume was not decreased by ipriflavone administration."
07/01/2001 - "The purpose of this study was to evaluate the efficacy of ipriflavone in preventing bone loss, decreasing in serum cholesterol and decreasing the rate of appearance of vasomotor symptoms, as well as the effects of ipriflavone on reduction of myoma volume by estrogen deficiency during treatment with the GnRH analog leuprolide. "
|2.||Gonadotropin-Releasing Hormone (GnRH)
|7.||salmon calcitonin (Calcimar)
|1.||Hormone Replacement Therapy (Therapy, Hormone Replacement)
|2.||Renal Dialysis (Hemodialysis)
|4.||Estrogen Replacement Therapy
|5.||Stapes Surgery (Stapedectomy)